

Curriculum vitae

Pieter Van Vlierberghe, 37 yr, PhD, Associate Professor

Affiliations: ¹ Center For Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium
² Cancer Research Institute Ghent, Ghent, Belgium

Office: Medical Research Building II – 110.006

De Pintelaan 185

9000 Ghent, Belgium

Tel: 003293321043

Email: pieter.vanvlierberghe@ugent.be

Education and training

1998-2003: KU Leuven, Leuven, Belgium. Engineer Cell and Gene Biotechnology

2003-2008: Erasmus University, Rotterdam, The Netherlands. PhD in Medical Sciences

Research and Professional experience

2008-2012: Postdoc, Institute for Cancer Genetics, Columbia University, New York, USA

2012-2014: Senior Postdoc, Faculty of Medicine, Ghent University, Ghent, Belgium

2015-current: Associate Professor, Faculty of Medicine, Ghent University, Ghent, Belgium

Significant Professional Activities and/or awards

2004: Recipient of the Rene Vogels Travel Award from Netherlands Organization for Scientific Research (NWO)

2004: Recipient of the Ter Meulen Fonds Travel Award from the Royal Netherlands Academy of Arts and Sciences (KNAW)

2011: Recipient of the American Society of Hematology (ASH) Scholar Award (2011)

2013: Recipient of Prize Albert Van Dyck for Leukemia Research (Belgian Royal Academy of Science)

2014: Selected for participation in the Translational Research Training in Hematology (TRTH) program from European Hematology Association/American Society of Hematology

2015: Member of the Editorial Board of the Scientific Journal Haematologica (IF = 7.702)

2015: Chair/Moderator of a session at the 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL, USA

2015: Recipient of a Starting Grant from the European Research Council (ERC)

2016: Recipient of the Swiss Bridge Award 2016 from the Swiss Bridge Foundation

2016: Chair/Moderator session of a session at the 58th ASH Annual Meeting & Exposition, December, 2016, San Diego, CA, USA

2017: Faculty member in the Translational Research Training in Hematology (TRTH) program from European Hematology Association/American Society of Hematology

- 2017: Co-organizer of the international T-cell ALL meeting, March 17-19 2017, Leuven, Belgium
- 2017: Member of the Editorial Board of the Scientific Journal Blood (IF = 13.164)
- 2017: Recipient AstraZeneca Foundation Award for Epigenetics
- 2018: Member of the Fellowships and Grants Committee of the European Hematology Association (EHA)
- 2018: Grant Baillet Latour for Medical Research - Belgium

Patents

Co-Inventor on Patent No. 1216-1-009PCT: "Methods and composition for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets".

Memberships of Scientific Associations

- 2008 – current: Member of the European Hematology Association (EHA)
- 2008 – current: Member of the American Society of Hematology (ASH)
- 2014 – current: Member of the American Association of Cancer Research (AACR)
- 2016 – current: Member of the Cancer Epigenetics Society

Current Research Team

The lab of normal and malignant hematopoiesis, headed by Dr Van Vlierberghe, currently consists of 7 postdocs, one bio-informatician, 3 PhD students and 3 technicians.

Research Output - Publications

Total number of publications	61
Total sum of citations	3586
H-index	27

Ten peer-reviewed publications that illustrate the applicant's scientific career

1. **Van Vlierberghe P**, Palomero T, Khiabani H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. (2010) PHF6 mutations in T-cell acute lymphoblastic leukemia. **Nature Genetics** 42:338-42. **Impact Factor 2010 = 36.38**
2. **Pieter Van Vlierberghe**, Alberto Ambesi-Impiombato, Arianne Perez-Garcia, J. Erika Haydu, Isaura Rigo, Michael Hadler, Valeria Tosello, Giusy Della Gatta, Elisabeth Paietta, Janis Racevskis, Selina M. Luger, Jacob M. Rowe, Montserrat Rue and Adolfo A Ferrando. *ETV6* mutations in early immature human T-cell leukemias. **Journal of Experimental Medicine** 2011 Dec 19;208(13):2571-9. **Impact Factor 2012 = 13.853**
3. Ntziachristos P*, Tsirigos A*, **Van Vlierberghe P***, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, De Keersmaecker K, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I. Genetic inactivation

- of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. **Nature Medicine**. 2012 Feb 6;18(2):298-301. *Co-first Authors. **Impact Factor 2012 = 22.462**
4. Jay P. Patel, Mithat Gonen, Maria E Figueroa, Omar Abdel-Wahab, Hugo Fernandez, Zhuoxin Sun, Janis Racevskis, **Pieter Van Vlierberghe**, Igor Dolgalev, Sabrena Thomas, Olga Aminova, Kety Huberman, Janice Cheng, Agnes Viale, Nicholas D. Socci, Adriana Heguy, Athena Cherry, Gail Vance, Rodney Higgins, Rhett P. Ketterling, Robert E. Gallagher, Mark Litzow, Jacob M. Rowe, Selina Luger, Adolfo Ferrando, Elisabeth Paietta, Martin S. Tallman, Ari Melnick and Ross L. Levine. Prognostic and therapeutic relevance of integrated mutational profiling in AML. **New England Journal of Medicine** 2012 Mar 22;366(12):1079-89. **Impact Factor 2012 = 51.658**
 5. Ntziachristos P, Tsirogos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, Mullanders J, Becksfort J, Nedjic J, Paietta E, Tallman MS, Rowe JM, Tonon G, Satoh T, Kruidenier L, Prinjha R, Akira S, **Van Vlierberghe P**, Ferrando AA, Jaenisch R, Mullighan CG, Aifantis I. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. **Nature**. 2014 Oct 23;514(7523):513-7. **Impact Factor 2014 = 41.456**
 6. Sofie Peirs, Filip Matthijssens, Steven Goossens, Inge Van de Walle, Katia Ruggero, Charles E. de Bock, Sandrine Degryse, Kirsten Canté-Barrett, Delphine Briot, Emmanuelle Clappier, Tim Lammens, Barbara De Moerloose, Yves Benoit, Bruce Poppe, Jules Meijerink, Jan Cools, Jean Soulier, Terence H. Rabbitts, Tom Taghon, Frank Speleman and **Pieter Van Vlierberghe**. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. **Blood** 2014 Dec 11;124(25):3738-47. **Impact Factor 2014 = 10.452**
 7. Joni Van der Meulen, Viraj Sanghvi, Konstantinos Mavrikakis, Kaat Durinck, Fang Fang, Filip Matthijssens, Pieter Rondou, Peter Vandenberghe, Eric Delabesse, Tim Lammens, Barbara De Moerloose, Björn Menten, Nadine Van Roy, Bruno Verhasselt, Bruce Poppe, Yves Benoit, Tom Taghon, Ari Melnick, Frank Speleman, Hans-Guido Wendel and **Pieter Van Vlierberghe**. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. **Blood** 2015 Jan 1;125(1):13-21. **Impact Factor 2015 = 11.847**
 8. Durinck K, Van Loocke W, Van der Meulen J, Van de Walle I, Ongenaert M, Rondou P, Wallaert A, de Bock CE, Van Roy N, Poppe B, Cools J, Soulier J, Taghon T, Speleman F and **Van Vlierberghe P**. Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia. **Leukemia**. 2015 Dec;29(12):2317-27. **Impact Factor 2015 = 12.104**
 9. Goossens S, Peirs S, Van Loocke W, Wang J, Takawy M, Matthijssens F, Sonderegger SE, Haigh K, Nguyen T, Vandamme N, Costa M, Carmichael C, Van Nieuwerburgh F, Deforce D, Kleefeld O, Curtis DJ, Berx G, Van **Vlierberghe P***, Haigh JJ*. Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. **Blood**. 2017 Feb 23;129(8):981-990. **Impact Factor 2015 = 11.841** *shared co-senior authors
 10. Sofie Peirs, Viktoras Frismantas, Filip Matthijssens, Wouter Van Loocke, Tim Pieters, Niels Vandamme, Béatrice Lintermans, Maria Pamela Dobay, Geert Berx, Bruce Poppe, Steven Goossens, Beat C Bornhauser, Jean-Pierre Bourquin and **Pieter Van Vlierberghe**. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. **Leukemia** 2017 Oct;31(10):2037-2047. **Impact Factor 2015 = 12.104**